Back to mobile site

ProQR (PRQR) Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for Treatment of LCA10

October 15, 2019 4:09 PM EDT Send to a Friend
ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login